Industry Archival Report · 2026-11-15 · Research Perspective: Brand Consumption
The subject of study is the Chinese pet economy, with the urban dog & cat consumption market as the primary caliber (Petdata White Paper), covering the three sub-segments required by the mandate, each accounted for separately:
| Sub-segment | Scope | 2025 Size | Share | 2025 Growth | Life-Cycle Stage |
|---|---|---|---|---|---|
| Pet food | Staple food/treats/prescription food/supplements | RMB 167.9bn | 53.7% | +5.9% | Mid-growth stage (structural upgrading-driven) |
| Pet healthcare | Diagnosis & treatment/drugs/vaccines/checkups | RMB 86.3bn | 27.6% | +2.6% | Mid-growth stage, short-term pressure (losing share) |
| Pet supplies | Cleaning/smart/toys & apparel | RMB 38.1bn | 12.2% | +2.5% | Traditional items mature, smart items growing |
| Pet services (incidental) | Grooming/boarding/training | RMB 20.3bn | 6.5% | -0.5% | Mature and rational stage |
The four items total RMB 312.6 billion, closing with the overall market. Excludes aquarium/exotic pets (Frost & Sullivan full-caliber: ~430 million pets in 2024, 570 million 2029E, with ~17.07 million exotic-pet owners—background only in this report).
One-sentence value chain map: Upstream animal health & raw materials (vaccines/veterinary drugs/chicken and other agricultural products) → Midstream manufacturing & brands (export OEM/ODM ↔ own brands, Shandong accounts for 56.4% of export volume) → Channels (online accounts for 68.3% of food retail: Taobao-Tmall/JD/Douyin; offline pet stores and hospital prescription channels) → Downstream services (treatment/grooming/boarding).
The key to competitive boundaries: This is a brand-consumption industry; the pricing power formula = channel exclusivity × food-switching cost × mindshare concentration ÷ platform traffic dependence—the last item is the funnel draining industry-wide profits, and the primary cause of the 2026 profit collapse.
Urban dog & cat consumption was RMB 300.2/312.6 billion in 2024/2025 (+7.5%/+4.1%). On volume: 126 million urban dogs & cats (+1.8%), of which cats at 72.89 million (+1.9%) keep outpacing dogs at 53.43 million (+1.6%); cats' consumption share rose to 48.6% (dogs 51.4%)—the "cat economy" mirrors the global pattern (Euromonitor: global cat food CAGR of 6% in 2020-2025 > dog food at 3.8%), and cat ownership is unconstrained by urban dog-keeping ordinances. On price: annual spend per dog RMB 3,006 (+1.5%), per cat RMB 2,085 (+3.2%)—both at record highs but with modest growth.
Upgrading side: Preference for fresh/baked/freeze-dried food has risen sharply; 39.2% of owners pay a premium for "fresher, healthier"; Gambol's staple food revenue +53.8%, premium sub-brand BAF up +79% across platforms during Double 11; Tmall Double 11 pet health category +50%. Down-trading side: JD staple food sales volume +21% in Jan-Jul 2025 but sales value only +11% (average price ~-8.3%); treatment satisfaction fell to 66.2% (opaque pricing is the top complaint); smart supplies saw low-price competition as new entrants flooded in. Conclusion: food is structurally moving up (domestic premium-value replacing imports), while healthcare and services are commoditizing toward value-for-money—both hold true simultaneously; any one-sided narrative is incomplete.
No visible inventory accumulation: Petpal's inventory in 2026H1 was only +1.05% vs. the start of the year; leaders produce to sell with healthy sell-through rates (Chanwan 106.5%). But online sits in the "high turnover + price war" quadrant (2025 618 pet food GMV RMB 7.5 billion across platforms, headline +36%), while offline pet stores/hospitals are in the "weak turnover + rationalization" quadrant. The real inventory risk lies in 2027: concentrated new capacity coming online + revenue growth down to single digits could restart the channel-stuffing cycle (see I3).
Assumptions: dog/cat population +1.2%/+1.5% per year (slightly lower than 2025 actual +1.6%/+1.9%), spend per dog/cat +2.5%/+3.5% per year (mid-point of the three-year trend), 2028E = 3126 + 429 ≈ RMB 355.5 billion.
Correction to the authoritative forecast: The Petdata White Paper forecasts RMB 405.0 billion for 2028 (CAGR 9%), 14% above this bridge. Independent review highlights two points: ① The White Paper's 2024 edition forecast for 2026 ran ~11% above the actual trajectory—a track record of systematic optimism; ② High-frequency data already show decay—pet food GMV growth across three major online platforms slowed from 10.6% in 2025 to 6.1% in 2026H1 (SWS Research citing Jiuxian data). This report adopts RMB 335.0-355.5 billion as the 2028E base-case range (CAGR 3.5%-4.4%), and flags "whether pet population growth can hold above 1.5%" and "whether per-pet spend growth is diluted by value-for-money trading down" as the largest uncertainties. The inflection is gradual in nature (the full chain of penetration × population × per-pet spend is quantified; no step-change events).
A-share leaders' capacity (2024-2025): Chanwan 163,800 tonnes (+56.8% in one year), Petpal ~91,500 tonnes (staple & wet food capacity doubled in a year), Gambol 100,000+ tonnes plus ~60,000 tonnes more from IPO fundraising projects. No official statistics exist on national nameplate capacity. Utilization polarization is the single most important fact on the supply side of this industry:
Chanwan's overall utilization is 72% (diluted by capacity additions), Petpal's chew lines are healthy at 74-80%, but Petpal's staple/wet food utilization is only 3.8%—concentrated new-line launches + falling overseas orders + avian flu disrupting shipments from New Zealand; its New Zealand plant needs 30-40% utilization to break even (2025 loss of RMB 66.22 million).
| Project | Entity | Capacity | Timing |
|---|---|---|---|
| Premium staple food project (Liaocheng) | Gambol | 300,000 t/yr | Announced 2026-08, 2-year build (production ~2028) |
| Dry food 60k t + wet food 40k t | Chanwan | 100,000 t/yr | Converting to fixed assets progressively from 2025 |
| New Zealand Pure Natural 70k t + domestic 50k t | Petpal | 120,000 t/yr | Dry food live; rest under construction |
Over 500,000 tonnes of new capacity in total, while leaders' revenue growth has already slowed to single digits (Gambol 2026Q1-3 revenue +8.2%). If domestic demand cannot absorb it, a mass-market staple food price war and channel stuffing in 2027-28 is this industry's biggest endogenous risk—this report has incorporated it into the bear-case scenario (probability 0.30, see I7).
① Production licenses (three-tier administration under the Administrative Measures for Pet Feed + label registration); ② Import registration: foreign feed approval + testing takes 6-12 months, valid 5 years—a time barrier against foreign entrants; ③ Prescription food has no separate license, but formulations/clinical data/hospital channels form de facto barriers; after the prescription food and freeze-dried industry standards took effect on 2026-05-01 (MOA Announcement No. 976, NY/T 4838/4839-2025), the compliance bar rose further; ④ Animal treatment licenses: hospitals require 3+ licensed veterinarians (vet licensing exam pass rate ~30%); ⑤ Brand spend thresholds: Gambol's 2025 selling expenses were RMB 1.527 billion—for a new brand, customer acquisition cost is the real barrier.
Gambol's 2025 gross margin by channel: direct 53.37% / distribution 38.24% / OEM 31.17%—direct sales exceed OEM by 22.2 percentage points, with own brands at 73.3% of revenue—the steepest "profit stratification curve" in the industry. Net margin divergence is more extreme: Gambol 9.96% in 2025 vs. collapsed to 4.18% in 2026Q1-3; Petpal 8.1%→2.4%; Yiyi 10.9%→5.7%. Premium price band: 2026 Double 11 Tmall flagship prices range from RMB 85.7/bag (leader) to RMB 250/bag (Instinct), a 2.9x spread end to end; prescription food in hospital channels carries a ~41% markup vs. e-commerce (280 vs. 198 yuan/bag), and in-hospital product sales gross margin of 43.7% is the highest-retention link in the whole chain.
12-Month ASP path (base case): premium staple food +3~5%; prescription food +5~8% (national standards + hospital inertia); mass-market staple food -2~0% (share grab before new capacity lands); treats/exports -5~10%; smart supplies -5~10% (white-label war); treatment ticket prices flat (suppressed by price-comparison transparency).
Top-KOL livestream chain cost ratios (commission + slot + traffic buying) can exceed 50%; Douyin's pet category saw 552,000 ads in the last 90 days from 2,100+ brands. Leading brands' selling expense ratios have climbed for three consecutive years: Gambol 21.8% in 2024→22.6% in 2025→24.2% in the first three quarters of 2026 (RMB 1.241/5.124 billion), with selling expense growth (+20.0%) 2.45x revenue growth (+8.2%); the expense increment of RMB 207 million accounts for ~69% of its RMB 300 million net profit decline—the profit collapse is driven mainly by the traffic tax, not gross margin (gross margin fell only 3.3pct, net margin fell 7.7pct). Chanwan 11.1%→13.5%, Tianyuan 9.0%→11.4%—the whole industry adds +2~3pct per year. It has reached the upper edge of the 15-25% expense band of mature US brands and is still rising. Convergence outlets are limited: self-broadcast replacing KOL broadcast, repeat purchases, and offline hospital channels (no traffic buying needed).
A triple squeeze stacking up: ① Traffic tax (as above); ② Tariffs and price pressure (US Section 301 additional 25% + tariffs stacked in 2025; average US tariff rate on China ~35.2% as of 2026-08, PIIE; Vietnam 20%/Cambodia 19% reciprocal tariffs); ③ Cost reversal (the 2025 tailwind of -10% broiler purchase prices reversed in 2026: avian flu in France drove grandparent stock imports to zero in Jan-May 2026, parent-stock chick prices rose from 50 to 60+ yuan/set, and leading chick companies expect a favorable market in 2026H2-2027—chicken prices will most likely be a headwind in 2027).
Pricing power ranking (strong→weak): Prescription food/pet drug foreign players (hospital channel exclusivity + food-switching cost + national standard barriers) > Leading domestic brands ("pricing power without pricing freedom," constrained by a 24% traffic tax) > Smart supplies single-product brands (7x premium decays with penetration) > Medical chains (eroded by price-comparison transparency, with profit upstream siphoned off by prescription food) > OEM (customer quotes dominate + bears the tariffs).
Note: Royal Canin is a Mars brand and Myfoodie a Gambol brand; group-level and single-brand figures are listed side by side for comparison only. Separately, the White Paper/Euromonitor approach puts Myfoodie at roughly 6.2-6.3% (likely including snacks and online weighting; not adopted as a headline). The six items in the chart total about 21%, based on Guotai Haitong's 2025 retail sales approach; this differs from the 2024 CICC/Euromonitor CR5 of 25.4% cited above in both year and methodology and is not directly comparable.
Two directions of share migration: ① Mars fell from 11.4% (2017) to 6.8% (2025, a 40% relative decline), while domestic brands reached 61% of the market in 2024, overtaking imports for the first time (aided by the tariff hike on imported retail pet food from 4% to 10%); ② but foreign players are fighting back in the premium and prescription segments—Royal Canin grew +39.4% online in 2025 and +44.4% in the first 7 months of 2026, with prescription products up +290%. Domestic substitution is largely complete in the mass segment but far from complete in the premium segment.
Brand matrix at a glance (price bands are estimates): Ultra-premium imported (Orijen/Acana 150-300 RMB/kg, Nature's Variety) → Domestic premium newcomers (Xianlang 60-120, Lanshi/Honest Bite 50-100, Fleigat 100-150) → Foreign premium via professional channels (Royal Canin 80-200, prescription diets 120-250) → Chinese and foreign mid-range (Pro Plan 40-80, Wanpy 30-80, Jueyan 40-120) → Mass value-for-money (Myfoodie 25-60, NetEase Yanxuan 20-50). Healthcare: dual chains of New Ruipeng (1,300+ hospitals in a tiered system) and Ruipai (548 hospitals, 4.8% of pet hospital revenue); Smart pet products: PETKIT/CATLINK/Homer (litter boxes 1,000-5,000 RMB/unit).
A counterpoint that must be confronted: leadership positions are not secure. In the 2026 618 Tmall all-category rankings, Xianlang took the top spot while Myfoodie slipped; the #1 single brand has changed roughly every three years (Royal Canin → Myfoodie → Xianlang); Yiyi's proposed acquisition of Gaoyejia in October 2025 collapsed four months later after the target's operations deviated from expectations. Share gains carry negative profit content (buying share with spending)—"consolidation toward the top" must be rewritten as "intense share migration with high-frequency leadership turnover; alpha comes from spending efficiency and product iteration capability, not static share." This is the biggest point of divergence between this report and market consensus.
Profits stay at the two ends: brands (own-brand gross margins 45-55%; Gambol's 2025 net profit attributable to parent of 673 million RMB, ROE 15.3%) and upstream animal health (Kepro Bio's net margin 43.9%; pet pharmaceuticals at 20.95 billion RMB in 2024, with Frost & Sullivan forecasting a 2025-2029E CAGR of 10.4%). The hollow middle: contract manufacturing (gross margins 16-22%, 2026 net margins 2.4-5.7%) and medical services (a market of 86.3 billion RMB with widespread losses: 24.5% of institutions loss-making, New Ruipeng losing about 1 billion RMB a year, Ruipai still loss-making after adjustments). Channel platforms are hidden rent-takers: industry selling expense ratios run roughly 12-24% (varying by company), with annualized traffic spend plus commissions in the tens of billions of RMB.
Migration direction over the next 2-3 years: ① Contract manufacturing → brands (highest certainty; Gambol's 73.3% own-brand share is the endpoint model; brand-less OEMs will exit); ② Within brands: profits consolidate toward "repeat-purchase mindshare + professional channel endorsement," while pure traffic-buying newcomers cede profits to platforms; ③ Animal health: domestic penetration rose from 18.5% (2020) to 39.5% (2025), with domestically produced feline triple vaccines exceeding 84% of batch releases—volume-based substitution is nearly complete, entering a second half of trading price for volume (Felocell collapsed from 120+ RMB/dose to 50-80 RMB, domestic products as low as 10 RMB, Ruimiaoshu discounting 33% at launch); the animal-health profit pool is shifting from "substitution dividend" to "price-war stress test"; ④ Healthcare: profits concentrate toward specialization and prescription-diet endorsement, but realization is very slow.
Bargaining power with counterparties: Weak upstream (agricultural inputs are priced at market); even weaker downstream—e-commerce platforms (expense ratios rising 2-3pct annually) and a handful of large overseas customers (Yiyi: 92.6% of revenue from overseas, 64.8% from North America, with no tariff hedging) siphon off the boom dividends at both ends, already validated by 2026 financials.
| Player | Positioning | 2025 Financials | One-Line Take |
|---|---|---|---|
| Gambol Pet 301498 | 73.3% own brand, domestic #1 | Revenue 6.769 bn (+29.1%), net margin 9.96%; 2026Q1-3 net profit -58.4% | Most like a branded consumer company, but 2026 shows the moat requires continuous paid maintenance |
| China Pet Foods 002891 | Snacks OEM origins, chasing in staple food | 5.221 bn (+16.9%), gross margin 29.5%; 2026H1 revenue +34.9%/net profit -37.6% | A specimen of OEM-to-brand transition pain: record revenue, yet gross margin falling |
| Peidi 300673 | Chew OEM (Southeast Asia capacity) | 1.449 bn (-12.7%); 2026Q1-3 net profit -77.5% | Overseas capacity is both an advantage and a vulnerability; domestic brand transition lags half a step |
| Yiyi 001206 | Global OEM leader in pet pads | 1.677 bn (-6.7%); 2026Q1-3 net profit -54.0% | Single category + 64.8% North America—double concentration; the OEM model's ceiling is visible |
| Tianyuan Pet 301335 | All-category OEM for pet supplies | 3.002 bn (+8.6%), net margin 1.4%; 2026Q1-3 -48.5% | Revenue #2, profits near zero: a textbook case of diseconomies of scale |
| Yuanfei Pet 001222 | Leash OEM transitioning to brand | 1.734 bn (+32.3%); 2026Q1-3 net profit -33.9% | In a front-loaded spending phase; right direction, quality yet to be proven |
| Ringpu Bio 300119 | Domestic top tier in animal health | 3.398 bn (+10.7%), pet segment ~858 mn; 2026Q1-3 net profit -17.5% | First-mover beneficiary of feline triple vaccine substitution, but already in the price-for-volume second half |
| Mars China (unlisted) | Foreign #1: 6.8% | Royal Canin China 2025 online 2.553 bn (+39.4%) | Share halved in a decade but counterattacking via prescription diets; domestic substitution far from complete |
| New Ruipeng (unlisted) | #1 in medical clinics (shrinking) | Annual loss ~1 bn; 2020-2022 cumulative losses 3 bn+ | "Organized but not consolidated"; integration has no winner |
| Ruipai (unlisted) | #2 in healthcare, 548 hospitals | 2024: 1.758 bn; nominally slightly profitable/loss after adjustments | IPO lapsed (prospectus expired 2026-06), a 2.82 bn RMB VAM obligation hangs overhead |
| PETKIT (unlisted) | Smart products leader | Not disclosed | Strongest single-product mindshare, but CR5 fell to 18% amid white-label siege |
Return quality: middling, with sharp divergence. Segments that earn real money: leading food brands (Gambol ROE 15.3%, dual engines of brand premium and supply chain) and animal-health vaccines (high net margins, but being diluted by price wars). Illusory-boom segments: ① in 2026 the whole sector grew revenue without profit (high revenue growth ≠ making money); ② medical services, an 86.3 bn RMB market, are broadly loss-making; ③ smart products show high growth, low concentration; ④ contract manufacturing—worst boom, weakest pricing power.
Valuation position: SW Feed index (the A-share anchor for pet food companies) at 63.0x PE, the 88th percentile since 2014; PB 2.21x, the 9th percentile (2026-11-13)—a classic case of "earnings collapse inflating PE while the asset side is no longer expensive." Individual stocks: Gambol PE TTM 37.7x/PB 3.09 (2nd percentile over the past year; the stock has retraced ~67% from its May 2025 high of 120+ RMB to below 40 RMB); China Pet Foods PE TTM 41.6x (97th percentile)/PB 2.61 (12th percentile); Peidi PE TTM 102.5x/PB 1.69 (3rd percentile). Boom conclusions must be cross-checked against valuations: this report's cautious bullishness rests on low PB plus conditional earnings recovery; if recovery fails, the high PE percentile means share prices are highly sensitive to 2027 delivery—this is a two-sided call of "asset-side support, unconfirmed earnings," not one-sided optimism that "the bottom is fully priced in."
Net direction: bullish (for leading compliant companies).
| Scenario | Probability | Narrative | Implication |
|---|---|---|---|
| Bear | 0.30 | Broiler prices rising in 2027 (breeding-stock gap transmission) + 500,000 tonnes of new capacity triggering price war + expense ratio breaking above 25%: leaders' net margins <5%, OEM <2%; 88th-percentile PE + earnings downgrades constitute a second-stage double kill | Avoid the whole sector; low-PB OEMs retain only event-option value |
| Base | 0.45 | Expense ratios peak in 2027H1 (22-24%), broiler-price headwinds offset by rising premium mix: leaders' net margins recover to 6-8% by end-2027 to 2028H1, food growth 4-6%, animal health trades price for volume, healthcare bottoms in an L | Buy share-migration alpha: leading brands + professional channels |
| Bull | 0.25 | Per-pet spending returns to +3.5%/yr + unexpected broiler-price decline + traffic inflation reverses + domestic prescription diets ramp: leaders' net margins 10-12%, healthcare chains turn positive after adjustment | Sector-wide recovery; export chain offers the biggest low-base elasticity |
| Timing | Event | Direction | Corresponds To |
|---|---|---|---|
| 2026-11~12 | Expiry/renewal judgment on US-China reciprocal tariff pause | OEM exports, both ways | D1/Export chain |
| 2026-12 | Gambol convertible bond and 300,000-tonne staple food project progress | Supply signal | D1 |
| 2027-01 | Paidu 2027 White Paper (growth <3% trips the bear trigger) | Demand validation | D1/D2 |
| 2027-03~04 | A-share 2026 annual + 2027Q1 reports: expense ratios/net margins | Earnings inflection | D1 |
| 2027H1 | Broiler chick prices (+10%+ YoY = cost headwind confirmed) | Costs | D1 |
| 2027-05 | Prescription-diet standard one year on: domestic share | Landscape | D2 |
| 2027-06~11 | 618/11.11: price discipline and brand-ranking turnover | Pricing power | D1/D2 |
| 2027-2028 | Concentrated 500,000-tonne new capacity release window | Price-war risk | D1 |
| Within 2027 | Whether Ruipai re-files | Healthcare inflection | D3 |
Interpretation: The upper-right "core allocation" contains only Gambol (boom up × best profit quality) and the unlisted Mars Royal Canin prescription business (strongest pricing power); the lower-right is the sector's value-trap zone—traffic newcomers (high growth but profits siphoned by platforms), smart products (white-label wars diluting a 7x premium), and animal-health feline triple vaccines (volume substitution nearly complete, unit prices collapsed to 10-80 RMB/dose; mistaking "substitution complete" for "dividends continuing" is a classic trap); China Pet Foods and medical chains sit on the lower-right edge (boom marginally positive, profit quality unproven/pending re-validation)—they are recovery options, not core allocations; lower-left "avoid" = OEM export chain and pet services. Bullish on the boom ≠ worth buying: within the market's +4% growth, the bulk of profits is captured by platform traffic taxes, overseas customers, and upstream prescription diets—be generous only to the brand side with pricing power.
Beneficiaries (base scenario):
Avoid (base scenario):
Note: The above is the sector-level center of gravity for the names; for names of interest (e.g., Gambol, China Pet Foods), separate profiles can be created for individual target prices and entry/exit points.
| Scenario | Biggest Winners | Biggest Losers |
|---|---|---|
| Bear (0.30) | Peidi/Yiyi (PB at 3-9% percentiles, nothing left to fall + tariff event option, relatively defensive) | Gambol/China Pet Foods (spending + price-war double kill, high-PE-percentile second-stage selloff) |
| Base (0.45) | Gambol (best spending efficiency, net margin recovering to 6-8%), China Pet Foods (global capacity + catch-up) | Tianyuan (net margin 1.4% with no buffer), traffic newcomers (cleared out when traffic funding dries up) |
| Bull (0.25) | Peidi (biggest low-base elasticity), Gambol (net margin back to 10-12%) | Tianyuan/medical chains (slowest recovery, underperform) |
① Demand growth steps down further (online GMV growth has already halved to 6.1%; if the 2027 White Paper shows growth <3%, base-case assumptions fail); ② price war from 500,000 tonnes of new capacity in 2027-28 vs. single-digit revenue growth; ③ structural rise in traffic costs (expense ratio breaking 25%); ④ US tariff reversals (pause expiring 2026-11) and tightening transshipment rules; ⑤ food-safety black swans (a single brand-destroying incident); ⑥ spread of urban pet-keeping restrictions suppressing dog population growth; ⑦ channel stuffing resuming at Gambol and other leaders after new capacity comes online.
Methodology and Data Notes: Market size and structure follow the Paidu "2026 China Pet Industry White Paper (Consumption Report)" (as republished by CCTV.com); brand shares follow Guotai Haitong's 2025 retail sales approach (with historical Euromonitor figures noted); healthcare supply follows Xinhua's survey approach; company financials are drawn from annual reports/analyst reports/exchange disclosures; valuation percentiles are as of 2026-11-13. Where sources conflict, one has been adopted and noted, with unadopted figures listed for cross-reference.